RIO DE JANEIRO, BRAZIL - The fully Brazilian nasal spray vaccine is still in its pre-clinical trial phase and lagging behind because of the lack of investment in science in Brazil.
World science has not stopped evolving because Brazil has invested little in local scientific research. While other countries have already approved vaccines against the novel coronavirus which are being produced on a large scale, developed by local companies, Brazilian science is crawling.
This lag is not for lack of effort. Infectologist Jorge Elias Kalil Filho and his team explain the challenges involved in the development of science in a . . .